Sionna Therapeutics Announces Positive Phase 1 Data for Nbd1 Stabilizers Sion-719 and Sion-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

THOMSON REUTERS
Jun 04

Sionna Therapeutics Announces Positive Phase 1 Data for Nbd1 Stabilizers Sion-719 and Sion-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10